MK-677 Raises GH and IGF-1.
Does It Deliver the Results People Want?

MK-677—also called ibutamoren or MK-0677—is an orally active small molecule, not a peptide, SARM or anabolic steroid. It activates the growth-hormone secretagogue receptor, GHSR-1a, the canonical ghrelin receptor. That can amplify the body’s own pulsatile GH release and raise circulating IGF-1 while leaving endogenous feedback loops in place.^[1][9][16]

The mechanism is attractive because GH and IGF-1 influence protein turnover, connective tissue, bone remodeling, substrate use and body composition. In human experiments, MK-677 has produced:

• larger GH pulses and higher IGF-1;
• improved nitrogen retention during short-term caloric restriction;
• higher DXA and four-compartment fat-free mass;
• changes in sleep architecture in very small studies; and
• increased biochemical markers of bone turnover.

Those are not imaginary benefits. They are also not interchangeable with myofibrillar hypertrophy, new contractile tissue, improved one-repetition maximum, faster sprinting, better recovery between training sessions or fewer injuries. Most adult trials enrolled older adults, men with obesity, people recovering from hip fracture or patients with disease—not resistance-trained lifters.^{[1][2][3][4][5][6][7]}

GH secretion declines with age, and GH-deficient states provide a strong proof of principle that restoring the axis changes body composition. MK-677 approaches the axis upstream: instead of supplying recombinant GH, it stimulates the receptor system that normally integrates ghrelin, hypothalamic signals and pituitary release. In young men, seven nightly doses raised GH secretion and IGF-1. In older adults, 25 mg daily restored average IGF-1 into a range described by investigators as typical of younger adults.^[1][9]

The acute biology also looks anabolic under energy stress. Eight healthy adults completed two calorie-restricted periods in a crossover experiment. During the week with placebo, average nitrogen balance remained negative at −1.48 g/day; with 25 mg MK-677 it was +0.31 g/day. Integrated nitrogen balance across the treatment week also favored MK-677. That is direct evidence that the compound altered whole-body protein economy during a tightly controlled catabolic challenge.^[3]

But nitrogen balance is whole-body accounting. It cannot locate retained protein inside biceps, quadriceps, liver, skin, connective tissue or expanding extracellular compartments. A positive balance over seven days is a mechanistic signal and a useful reason to run a training study—not a photograph of new muscle fibers.

The most informative study randomized healthy adults aged 60–81 to MK-677 25 mg daily or placebo in a two-year modified-crossover design. Sixty-five participants entered the pivotal first year. At 12 months, fat-free mass increased 1.1 kg (95% CI 0.7 to 1.5) with MK-677 and decreased 0.5 kg (−1.1 to 0.2) with placebo—a relative difference of about 1.6 kg. Appendicular lean mass rose by 0.5 kg with MK-677 while declining 0.3 kg with placebo. Intracellular-water-based body cell mass also favored the drug.^[1]

Those findings make it too dismissive to say “it is all water.” The four-compartment model and body-cell-mass analysis suggest that the effect was not merely a DXA artifact from extracellular edema. Yet the opposite overreach is equally wrong: fat-free mass includes muscle, water, organs, glycogen and connective tissues. The trial did not biopsy muscle or quantify fiber cross-sectional area.

Body weight rose 2.7 kg (95% CI 2.0 to 3.5) with MK-677 versus 0.8 kg (−0.3 to 1.8) with placebo. Limb fat increased more with MK-677. Most importantly, the added fat-free mass did not improve isokinetic strength, physical function or quality of life. The study was not powered primarily for functional endpoints, and these were older adults rather than lifters following progressive training. Still, a year is long enough that a dramatic performance effect should not be assumed away.^[1]

In 24 men with obesity, 25 mg daily for eight weeks raised IGF-1 roughly 40% and increased fat-free mass by both DXA and a four-compartment model. Total and visceral fat did not significantly change. Basal metabolic rate increased at week two but was no longer statistically significant at week eight. An oral glucose-tolerance test showed impaired glucose homeostasis at both measured time points.^[2]

In hip-fracture recovery, the signal again outran the outcome. An earlier trial produced directionally favorable changes in several lower-extremity measures, but between-group differences were not statistically conclusive. A later phase IIb study randomized 123 older patients to 25 mg daily or placebo for up to 24 weeks. IGF-1 increased by 51.4 ng/mL relative to placebo. Gait speed improved on the study’s rank scale, but stair-climbing power and most other functional measures did not. The trial ended early after a congestive-heart-failure safety signal.^[6][7]

The largest trial was not a muscle study. In 563 people with mild-to-moderate Alzheimer disease, 25 mg daily for 12 months increased IGF-1 but did not slow clinical progression on cognition, global change, activities of daily living or dementia severity. That null result does not answer hypertrophy, but it reinforces the same principle: stronger target engagement does not guarantee the outcome chosen for the trial.^[8]

Small sleep experiments remain interesting. In eight young adults, the higher exposure increased stage-IV and REM sleep; in six older adults, REM duration increased and REM latency shortened. These were tiny, short studies with architecture endpoints—not modern trials showing better next-day recovery, training performance or long-term health. Bone studies likewise measured turnover markers, not fewer fractures or stronger athletic bone.^[4][5][10]

Performance users are not irrational to find this dataset exciting. A once-daily oral molecule produced sustained endocrine target engagement and measurable body-composition change. The missing experiment is obvious: randomize trained adults to MK-677 or placebo while standardizing progressive resistance training, protein intake and energy balance; then measure muscle size, strength, performance, fluid compartments and glucose physiology.

Without that trial, three major extrapolations remain:

1. Population: older or metabolically different adults may respond differently from trained young adults.
2. Intervention: MK-677 alone is not evidence for stacks with GH, insulin, androgens or peptides. Interactions can change both efficacy and risk.
3. Endpoint: GH, IGF-1, nitrogen balance and fat-free mass do not equal contractile hypertrophy or better training adaptation.

There is also no head-to-head randomized trial showing that MK-677 produces the same body-composition, strength or safety profile as injected GH. Both raise the axis, but the temporal pattern, receptor context, appetite effect and exposure control differ. “Oral GH” is memorable shorthand and poor pharmacology.

GHSR-1a is not a muscle-specific switch. Ghrelin signaling affects appetite and energy balance; GH affects fluid and glucose physiology. In the older-adult trial, appetite commonly increased before subsiding, mild lower-extremity edema and muscle pain occurred, fasting glucose rose by an average 0.3 mmol/L (5 mg/dL), and insulin sensitivity decreased. Cortisol increased modestly. Body weight increased substantially more than fat-free mass.^[1]

The later hip-fracture trial is the more serious warning. It was stopped early after congestive heart failure appeared as a safety signal in a vulnerable older population. That does not prove the same absolute risk in young healthy adults; it does prove that “endogenous GH release” is not synonymous with “risk free.”^[7]

FDA’s 2024 compounding review identified concerns including congestive heart failure, hyperglycemia, elevated liver enzymes, edema and fluid overload, along with musculoskeletal pain, appetite increase and hyperprolactinemia. The Pharmacy Compounding Advisory Committee voted 13–1 against including ibutamoren mesylate on the 503A Bulks List. FDA also states that ibutamoren is not an approved drug and does not qualify as a dietary ingredient; products sold online therefore add identity, purity and labeling uncertainty to the pharmacology itself.^{[11][12][13][14]}

Pediatric development under the name LUM-201 deserves its own context. Acute GH-response studies in children with diagnosed GH deficiency are designed around growth velocity and treatment selection. They should not be repackaged as evidence for adult muscle enhancement.^[15]

A decisive study does not need to be enormous, but it must be built around the actual claim. It should preregister a primary endpoint, keep training and protein exposure comparable, use blinded placebo control, and distinguish intracellular from extracellular changes. Because glucose and fluid signals are already known, safety cannot be an afterthought.

The most informative result would not simply be “IGF-1 increased.” We already know that. It would report how many additional millimeters or cubic centimeters of muscle were gained, whether force rose proportionally, how much weight was water or fat, whether the effect persisted after discontinuation, and what metabolic price accompanied it.

MK-677 is mechanistically credible and biologically active in humans. It repeatedly raises GH and IGF-1. It improved short-term nitrogen balance under caloric restriction and produced a meaningful fat-free-mass difference over one year in older adults. Those are real findings and a legitimate foundation for more research.

The hypertrophy promise is still an extrapolation. The best long trial found no corresponding strength or functional improvement. No robust randomized trial has shown extra contractile muscle or performance on top of standardized resistance training in healthy lifters. Appetite, additional body weight, fluid retention and worse glucose regulation complicate the simplistic “more GH equals lean gains” story.

The exciting conclusion is not that the compound has failed. It is that researchers have already cleared the first half of the bridge—target engagement and body composition—and left the question the performance community actually cares about unanswered. MK-677 deserves a modern, well-controlled hypertrophy trial precisely because the mechanism and early human signals are strong enough to make the result worth knowing.